Guard Therapeutics International AB (GUARD) AI Stock Analysis

• Market Cap: kr33.68M
• Dividend Yield: N/A
• Average Volume (3M): 44.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.69
• Revenue Growth: N/A
• EPS Growth: 0.30%
• Country: SE
• Employees: 12
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.81
• Shares Outstanding: 20,167,631
• 10 Day Avg. Volume: 59,609
• 30 Day Avg. Volume: 44,153
• PEG Ratio: <0.01
• Price to Book (P/B): 0.65
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -1.04
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: kr1.50 ▲(8.70% Upside)
• Action: Reiterated Date: 02/21/26
• Date: Action: Reiterated 02/21/26

The score is primarily driven by weak financial performance (no revenue, large ongoing losses, and sustained cash burn that has reduced equity/assets), with technical indicators also showing a broadly weak longer-term trend. Valuation contributes limited support because the negative P/E reflects losses and no dividend yield data is available.

Positive Factors

No debt

The absence of recorded debt reduces mandatory interest and refinancing obligations, preserving strategic optionality across long clinical timelines. This lowers immediate cash drain and financial distress risk, allowing management to focus capital on development milestones rather than servicing debt.

Focused kidney disease pipeline

A concentrated R&D mandate on AKI and renal indications creates a clear strategic thesis and specialization. Focused expertise can improve trial design, attract targeted collaborators and payers, and support a differentiated clinical and commercial positioning if the pipeline advances.

Lean operating structure

A small headcount implies a lean cost base and lower fixed overhead, which can extend runway per funding round. For a clinical-stage biotech, this allows flexible outsourcing of trials and manufacturing and can improve capital efficiency while programs are advanced.

Negative Factors

No revenue; persistent losses

Absence of any revenue through 2025 and continued large losses means the company lacks commercial cash generation. Long-term viability depends on external financing; this structural revenue gap raises sustained execution and funding risk until commercialization is achieved.

Depleted equity and assets

Material erosion of equity and assets over a few years weakens the balance sheet buffer against clinical or development setbacks. Reduced capital base limits financial flexibility, increases sensitivity to adverse events, and heightens likelihood of dilutive financing needs.

Heavy negative operating cash flow

Sustained and large negative operating cash flow demonstrates ongoing cash consumption tied to operations and development. This persistent burn requires frequent external capital, increasing financing risk, potential dilution, or program pacing compromises over the medium term.

Guard Therapeutics International AB Business Overview & Revenue Model

Company Description

Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.

How the Company Makes Money

Guard Therapeutics primarily makes money through the development and potential commercialization of its drug candidate, ROSgard. Revenue streams include potential milestone payments, royalties, and licensing agreements with pharmaceutical companies upon successful regulatory approval and commercialization. The company may also receive funding through research grants, partnerships, and collaborations with other biotech firms or research institutions. Significant factors contributing to its earnings include the successful advancement of ROSgard through clinical trials and securing strategic partnerships for distribution and marketing.

Guard Therapeutics International AB Financial Statement Overview

Summary

No revenue across 2020–2025 with large, persistent losses and heavy cash burn. While the company has no debt, equity and assets have fallen sharply, increasing longer-term funding risk.

Income Statement

The company has generated no revenue across the provided annual periods (2020–2025), while losses remain very large and persistent. Net losses were substantial each year and expanded again in 2025 (net income: -108.9M vs. -96.1M in 2024), indicating continued heavy spending without visible commercial traction in the reported figures. The main positive is that profitability improved briefly in 2024 versus 2023 before deteriorating again in 2025, but overall earnings quality is weak given the ongoing loss profile and lack of revenue base.

Balance Sheet

A key strength is the absence of debt in every year shown, which reduces financial risk and refinancing pressure. However, the balance sheet has weakened materially: equity declined sharply from 177.4M (2022) to 40.6M (2025), and total assets fell from 202.6M (2022) to 54.1M (2025), consistent with sustained cash burn and depletion of resources. Returns to shareholders are deeply negative (e.g., return on equity in 2024: about -2.53), highlighting that losses are large relative to the remaining equity base.

Cash Flow

Operating cash flow is consistently and heavily negative each year, reflecting ongoing cash consumption (2025: -109.4M; 2024: -94.8M; 2023: -116.0M). Free cash flow is also meaningfully negative where provided (e.g., 2024: -94.8M; 2023: -116.0M; 2022: -102.1M), and the year-to-year pattern is volatile rather than steadily improving. While free cash flow roughly tracks reported losses in several years (suggesting limited non-cash distortion), the scale of cash burn relative to the shrinking asset and equity base elevates funding risk over time.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	-15.00K	-15.00K	-15.00K
EBITDA	-123.13M	-107.74M	-100.23M	-114.91M	-112.82M	-82.01M
Net Income	-124.12M	-108.85M	-96.07M	-113.32M	-110.76M	-82.16M
Balance Sheet
Total Assets	101.87M	54.14M	55.74M	85.23M	202.60M	190.44M
Cash, Cash Equivalents and Short-Term Investments	100.48M	49.83M	54.19M	83.74M	201.01M	188.60M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	21.47M	13.51M	17.77M	18.49M	25.24M	14.66M
Stockholders Equity	80.40M	40.63M	37.97M	66.73M	177.36M	175.78M
Cash Flow
Free Cash Flow	-116.98M	0.00	-94.75M	-116.05M	-102.14M	-77.59M
Operating Cash Flow	-116.98M	-109.35M	-94.75M	-116.05M	-102.14M	-77.59M
Investing Cash Flow	0.00	0.00	0.00	0.00	-1.00K	0.00
Financing Cash Flow	126.37M	107.22M	62.66M	-779.00K	112.60M	176.30M

Guard Therapeutics International AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.38
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GUARD, the sentiment is Negative. The current price of 1.38 is below the 20-day moving average (MA) of 1.70, below the 50-day MA of 1.70, and below the 200-day MA of 12.35, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 45.69 is Neutral, neither overbought nor oversold. The STOCH value of 48.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:GUARD.

Guard Therapeutics International AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XBRANE	46 Neutral	kr130.84M	0.48	-16.90%	―	4.64%	―
CLBIO	46 Neutral	kr405.97M	-26.73	―	―	―	―
ACE	44 Neutral	kr397.73M	-4.56	-79.60%	―	―	31.62%
IVACC	44 Neutral	kr207.21M	-2.19	-25.66%	―	127.13%	56.91%
IMMU	43 Neutral	kr284.74M	-2.14	-16.51%	―	―	31.37%
GUARD	42 Neutral	kr33.68M	-0.26	-199.25%	―	―	0.30%